Why COVID-19 Silent Hypoxemia is Baffling to Physicians

Martin J. Tobin MD, Franco Laghi, MD, Amal Jubran, MD

Division of Pulmonary and Critical Care Medicine,

Hines Veterans Affairs Hospital and Loyola University of Chicago Stritch School of Medicine,

Hines, Illinois 60141

Corresponding author:

Martin J Tobin; Division of Pulmonary and Critical Care Medicine

Edward Hines Jr. VA Hospital, 111N; 5000 South 5th Avenue; Hines, Illinois 60141

E-mail address: mtobin2@lumc.edu Tel:(708) 202-2705

Funding Source: National Institute of Nursing Research (RO1-NR016055) and

Merit Review Award, Veterans Administration Research (1 I01 RX002803-01A1)

Words in body of manuscript= 2140

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints please contact Diane Gern (dgern@thoracic.org).
Abstract

Patients with COVID-19 are described as exhibiting oxygen levels incompatible with life without dyspnea. The pairing—dubbed happy hypoxia, but more precisely termed silent hypoxemia—is especially bewildering to physicians and is considered as defying basic biology. This combination has attracted extensive coverage in media but has not been discussed in medical journals. It is possible that coronavirus has an idiosyncratic action on receptors involved in chemosensitivity to oxygen, but well-established pathophysiological mechanisms can account for most, if not all, cases of silent hypoxemia. These mechanisms include how dyspnea and the respiratory centers respond to low levels of oxygen, how prevailing carbon dioxide tensions (PaCO₂) blunt the brain’s response to hypoxia, effects of disease and age on control of breathing, inaccuracy of pulse oximetry at low oxygen saturations, and temperature-induced shifts in the oxygen dissociation curve. Without knowledge of these mechanisms, physicians caring for hypoxemic patients free of dyspnea are operating in the dark—placing vulnerable COVID-19 patients at considerable risk. In conclusion, features about COVID-19 that physicians find baffling become less strange when viewed in the light of long-established principles of respiratory physiology; an understanding of these mechanisms will enhance patient care if the much-anticipated second wave emerges.

Abstract Words=199 words
Case Report Vignettes

MD, 64-year-old man, tested positive for SARS-CoV-2 and was diagnosed with COVID-19. While receiving 6 liters/min oxygen by nasal cannula, pulse oximetry saturation (SpO\textsubscript{2}) was 68% and arterial blood gas revealed oxygen tension (PaO\textsubscript{2}) 37 mmHg, carbon dioxide tension (PaCO\textsubscript{2}) 41 mmHg, and arterial oxygen saturation (SaO\textsubscript{2}) 75%. Upon questioning, he consistently denied any difficulty with breathing. On examination, he was comfortable, not using accessory muscles of respiration. Comorbidities included diabetes mellitus, hypertension, coronary artery disease and bypass surgery, left carotid endarterectomy, and renal transplantation.

RM, 74-year-old man, tested positive for SARS-CoV-2 and was diagnosed with COVID-19. While receiving 15 liters/min oxygen by reservoir mask, SpO\textsubscript{2} was 62% and arterial blood gas revealed PaO\textsubscript{2} 36 mmHg, PaCO\textsubscript{2} 34 mmHg, and SaO\textsubscript{2} 69%. Upon questioning, he consistently denied any difficulty with breathing (including while drinking). On examination, he was comfortable and not using accessory muscles of respiration. He did not have any comorbidity.

EF, 58-year-old man, tested positive for SARS-CoV-2 and was diagnosed with COVID-19. While receiving high-flow nasal cannula, SpO\textsubscript{2} was 76% and arterial blood gas revealed PaO\textsubscript{2} 45 mmHg, PaCO\textsubscript{2} 38 mmHg, and SaO\textsubscript{2} 83%. Upon questioning, he consistently denied any difficulty with breathing. On examination he was comfortable, using his cell phone. He had no known comorbidities.
The Wall Street Journal considers it a medical mystery as to why “large numbers of Covid-19 patients arrive at hospitals with blood-oxygen levels so low they should be unconscious or on the verge of organ failure. Instead they are awake, talking—not struggling to breathe” (1). Science judges the lack of patient discomfort at extraordinarily low blood-oxygen levels as defying basic biology (2). Writing in The New York Times, Dr. Levitan, with 30 years of emergency medicine experience, notes “A vast majority of Covid pneumonia patients I met had remarkably low oxygen saturations at triage—seemingly incompatible with life—but they were using their cellphones…they had relatively minimal apparent distress, despite dangerously low oxygen levels” (3). Despite this extensive coverage in the news media, the topic has not been addressed in medical journals.

Several factors explain why oxygen readings and lack of dyspnea in COVID-19 patients are baffling to physicians: effect of hypoxia on the respiratory centers, effect of PaCO$_2$ on the ventilatory response to hypoxia, hypoxia threshold that precipitates dyspnea, limited accuracy of SpO$_2$ below 80%, shifts in the oxygen-dissociation curve, tolerance of low oxygen levels, and the definition of hypoxemia.

Dyspnea and control of breathing

Viral infection of the respiratory system typically provokes inflammation and stimulation of sensory receptors, inducing transmission of afferent impulses to the respiratory centers (4). If the virus involves the alveoli, it may produce hypoxemia (5). The presence of dyspnea would be no physiological surprise in either situation. Surprise would arise only if sensory afferents or hypoxemia elicited significant stimulation of the respiratory centers and the patient did not develop dyspnea (6).
Unpleasant breathing can be recognized only by a patient: it is purely a subjective symptom (6). Caregivers commonly equate physical signs—tachypnea, tachycardia, facial expression—with dyspnea. This is wrong. Patients vary widely in behavioral responses to discomfort. As with pain, physical signs may overestimate or underestimate patient discomfort (7).

The respiratory centers are exquisitely sensitive to CO$_2$ (7). Small increases in PaCO$_2$ rapidly evoke large increases in minute ventilation; an increase in PaCO$_2$ of 10 mmHg produces a level of respiratory discomfort that cannot be tolerated for even a few minutes (8). Abnormal lung mechanics also provokes dyspnea, but considerably less than with hypercapnia (7).

Hypoxemia produces dyspnea through stimulation of the carotid bodies, which send signals to the medulla oblongata (9). The resulting increase in respiratory center output is transmitted down to the phrenic nerves and diaphragm causing increased minute ventilation (10). Heightened medullary center activity is concurrently transmitted up to the cerebral cortex. It is this cortical projection (corollary discharge) that produces the unpleasant sensation of dyspnea (7).

The ventilatory response to hypoxia is characterized as a hyperbolic curve (11). Minute ventilation is unchanged as PaO$_2$ drops from 90 to 60 mmHg; further decreases in PaO$_2$ provoke an exponential increase in minute ventilation (Figure 1). Moosavi et al (12) observed that the level of hypoxia required to induce the ventilatory response to hypoxia is equivalent to that required to induce dyspnea. A fall in end-tidal PO$_2$ below 60 mmHg elicited a strong increase in dyspnea in only half of subjects (12). The ventilatory and dyspnea responses to hypoxia are heavily influenced by prevailing PaCO$_2$. Severe hypoxia elicits an effective increase in ventilation only when background PaCO$_2$ exceeds 39 mmHg (12, 13).
We undertook an informal poll of 58 hospitalists, emergency physicians, and intensivists, inquiring if they had seen patients who might be regarded as having silent hypoxemia or “happy hypoxia” (the term used by newspapers). Of 37 respondents, 15 did not provide useful data. Nineteen patients had arterial blood gases; 16 had PaO$_2$ less than 60 mmHg and the patient communicated to a physician that he or she was not experiencing difficulty with breathing. Seven of the 16 patients had PaCO$_2$ levels above 39 mmHg (range, 41-49), which combined with PaO$_2$ of less than 60 mmHg would be expected to induce dyspnea; we considered these patients to have probable silent hypoxemia (see above vignette for patient MD). Nine patients had PaCO$_2$ levels below 39 mmHg (range, 29-37), which can blunt the respiratory centers; we do not categorize these patients as silent hypoxemia (see patient RM and EF vignettes).

A disproportionate number of COVID-19 patients are elderly and diabetic (14). Both factors blunt the response of the respiratory control system to hypoxia. The ventilatory response to hypoxia is decreased by 50% in people older than 65 years (15, 16). Given that dyspnea response to hypoxia parallels the ventilatory response (12), it is likely that older COVID-19 patients are more prone to silent hypoxemia. All but two of our 7 patients with probable silent hypoxemia were 64 years or older (age range 59 to 85 years). The ventilatory response to hypoxia is decreased by more than 50% in diabetes (17, 18). Diabetics also have a 1.8-fold impaired ability to perceive respiratory sensations (19). A further confounding factor is the broad range in respiratory drive between individuals (20). Chemical drive to breathe (in response to hypercapnia and hypoxia) exhibits as much as 300% to 600% variation between one subject and the next (20-23). This wide variability in respiratory drive is another factor that explains why some hypoxic patients do not develop dyspnea.
Hypoxemia as a threat to life

Physicians are fearful of hypoxemia, and many view saturations in the 80s as life threatening. We served as volunteers in an experiment probing the effect of hypoxemia on breathing pattern; our pulse oximeter displayed SpO$_2$ of 80% for over an hour and we were not able to sense differences between SpO$_2$ of 80% versus 90% (24). In investigations on control of breathing and oximeter accuracy, subjects experience SpO$_2$ of 75% (12), or briefly 45% (25), without serious harm. Tourists on drives to the top of Mount Evans near Denver experience oxygen saturations of 65% for prolonged periods; many are comfortable while some sense dyspnea (25).

Pulse oximetry

Pulse oximetry estimates arterial oxygen saturation by illuminating the skin and measuring changes in light absorption of oxyhemoglobin and reduced hemoglobin (26). Oximetry estimated saturation (SpO$_2$) can differ from true arterial oxygen saturation (SaO$_2$, measured with a CO-oximeter) by as much as ±4% (5). Oximetry is considerably less accurate at SaO$_2$ below 80%, partly because of the challenge in obtaining human calibration data (and guarding of information through trade secrets and patent protection). SpO$_2$ underestimated true SaO$_2$ by 7% in all three patients in the above vignettes. In subjects exposed to profound hypoxemia in a hypobaric chamber, resulting in arterial oxygen tension (PaO$_2$) of 21.6–27.8 mmHg (27), the mean difference and limits of agreement between pulse oximetry SpO$_2$ and true SaO$_2$ were -5.8±16%; when SpO$_2$ displayed <40%, 80% of simultaneous SaO$_2$ values were 10% higher (some were 30% higher)(28) (Figure 2).

Pulse oximetry is less reliable in critically ill patients than in healthy volunteers. In critically ill patients, the 95% limits of agreement between SpO$_2$ and SaO$_2$ was ± 4.02%, and the difference
between $\text{SpO}_2$ and $\text{SaO}_2$ over time was not reproducible (in magnitude or direction) (29). Oximetry is less accurate in black than in white patients: 2.45 times less accurate at detecting $\geq 4\%$ difference between $\text{SpO}_2$ and $\text{SaO}_2$ (30). Claims that COVID-19 patients had oxygenation levels incompatible with life may have arisen because caregivers are not aware that pulse oximeters are inherently inaccurate at low saturations and further impacted by critical illness and skin pigmentation.

**Shifts in oxygen-dissociation curve**

A shift in the oxygen-dissociation curve is another confounding factor. Fever, prominent with COVID-19, causes the curve to shift to the right; any given $\text{PaO}_2$ will be associated with a lower $\text{SaO}_2$ (Figure 3). At temperature $37^\circ\text{C}$, $\text{PaO}_2$ 60 mmHg (at normal pH and $\text{PaCO}_2$) will be accompanied by $\text{SaO}_2$ 91.1%. Temperature elevation to $40^\circ\text{C}$ will produce $\text{SaO}_2$ 85.8% (5.3% decrease) (31). Respective numbers at $\text{PaO}_2$ 40 mmHg are $\text{SaO}_2$ 74.1% at temperature $37^\circ\text{C}$ and $\text{SaO}_2$ 64.2% at temperature $40^\circ\text{C}$ (9.9% decrease) (31). These shifts produce substantial desaturations without change in chemoreceptor stimulation (because carotid bodies respond only to $\text{PaO}_2$, and not $\text{SaO}_2$) (9)—another factor contributing to silent hypoxemia.

**Mechanism of silent hypoxemia**

Given that COVID-19 patients exhibit several unusual findings, it is possible the virus has an idiosyncratic effect on the respiratory control system.

Angiotensin-converting enzyme 2 (ACE2), the cell receptor of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19, is expressed in the carotid body, the site at which chemoreceptors sense oxygen (32). ACE2 receptors are also expressed in
nasal mucosa. Anosmia-hyposmia occurs in two-thirds of COVID-19 patients (33) and the olfactory bulb provides a passage along which certain coronaviruses enter the brain (34). Whether SARS-CoV-2 gains access to the brain through the olfactory bulb and contributes to the association between anosmia-hyposmia and dyspnea (33) and whether ACE2 receptors play a role in the depressed dyspnea response in COVID-19 remains to be determined.

*Science* (2) links silent hypoxemia to the development of thrombi within the pulmonary vasculature. Increased thrombogenesis has been noted in COVID-19 patients (35). Thrombi within the pulmonary vasculature can cause severe hypoxemia, and dyspnea is related to pulmonary vascular obstruction and its consequences (36). Dyspnea can also arise from release of histamine or stimulation of J-receptors within the pulmonary vasculature. No biological mechanism exists, however, whereby thrombi in the pulmonary vasculature cause blunting of dyspnea (producing silent hypoxemia).

**Definition of hypoxemia**

*Stedman's Medical Dictionary* defines hypoxemia as “subnormal oxygenation of arterial blood, short of anoxia” (37). Clinicians, however, need to be mindful of the inverse relationship between PaO₂ and age; a PaO₂ of 66 mmHg can be normal in a 80-year old person (38, 39). In the 1990s, hypoxemia was commonly viewed as low PaO₂, and fractional inspired oxygen concentration (FＩO₂) was excluded from consideration (40, 41). Pierson, for example, specified that a mechanically ventilated patient with acute respiratory distress syndrome receiving 100% oxygen and PaO₂ 80 mmHg should not be labelled hypoxemic (42).

There is, of course, no pure essentialist definition of hypoxemia—merely a usage (40). To arrive at a present-day nominalist definition of hypoxemia, it appears that few physicians view
hypoxemia in the same manner as Pierson. In our informal poll of physicians caring for COVID-19 patients, we specified “I am NOT looking for oxygen requirements, like the number of liters being delivered.” Yet 77.3% of the respondents provided considerable detail on the level of supplemental oxygen, and 36.4% viewed SpO₂ of 90% or higher as compatible with hypoxemia. Although more detailed investigation is necessary, it appears that physicians today commonly define hypoxemia in terms of the amount of oxygen being supplied to a patient.

Judging severity of hypoxemia on the basis of supplemental oxygen is inherently problematic because F₁O₂ is impossible to estimate unless a patient is intubated or breathing room air. With a nasal cannula at 2 L/minute, F₁O₂ ranges anywhere between 24% and 35% (43). To minimize risk of hypoxemia, physicians frequently prescribe oxygen at a level far exceeding physiological needs. Given the flatness of the upper oxygen-dissociation curve, a pulse oximetry reading of 95% can signify PaO₂ anywhere between 60 and 200 mmHg (26, 44)—values that signify markedly different levels of gas-exchange impairment, especially in a patient receiving a high F₁O₂.

Given that hypoxemia is at the very heart of the most severe cases of COVID-19, one wonders if the lack of a widely accepted definition of hypoxemia contributes to some of the confusion and counterclaims associated with the disease.

In conclusion COVID-19 has engendered many surprises, but features that baffle physicians are less strange when contemplated through the lens of long-established principles of respiratory physiology (45).

Words in body of manuscript= 2140
Acknowledgement

We thank Marina Saad, MD for construction of the oxygen-dissociation curve based on the digital subroutine of Kelman.
References

1. Toy S, Roland, D. Some doctors pull back on using ventilators to treat Covid-19. *The Wall Street Journal* May 11, 2020.

2. Couzin-Frankel J. The mystery of the pandemic's ‘happy hypoxia’. *Science* 2020; 368(6490): 455-456.

3. Levitan R. The infection that’s silently killing coronavirus patients. *The New York Times*; April 20, 2020.

4. Preas HL, Jubran A, Vandivier RW, Reda D, Godin PJ, Banks SM, Tobin MJ, Suffredini AF. Effect of endotoxin on ventilation and breath variability: role of cyclooxygenase pathway. *Am J Respir Crit Care Med* 2001; 164: 620-626.

5. Tobin MJ. Basing respiratory management of coronavirus on physiological principles. *Am J Respir Crit Care Med* 2020: Apr 13. doi: 10.1164/rccm.202004-201076ED.

6. Tobin MJ. Dyspnea: pathophysiologic basis, clinical presentation, and management. *Arch Intern Med* 1990; 150: 1604-1613.

7. Banzett RB, Similowski T, Brown R. Addressing respiratory discomfort in the ventilated patient. In: Tobin MJ, editor. Principles and Practice of Mechanical Ventilation, 3rd ed. New York,: McGraw-Hill Inc.; 2012. p. p.1265-1280.

8. Banzett RB, Lansing RW, Evans KC, Shea SA. Stimulus-response characteristics of CO2-induced air hunger in normal subjects. *Respir Physiol* 1996; 103: 19-31.
9. Tobin MJ, Laghi F, Jubran A. Ventilatory failure, ventilator support, and ventilator weaning. Comprehensive Physiology (Handbook of Physiology, American Physiological Society) 2012; 2: 2871-2921.

10. Tobin MJ, Gardner WN. Monitoring of the control of ventilation. In: Tobin MJ, editor. Principles and Practice of Intensive Care Monitoring. New York: McGraw-Hill, Inc.; 1998. p. p. 415-464.

11. Weil JV, Byrne-Quinn E, Sodal IE, Friesen WO, Underhill B, Filley GF, Grover RF. Hypoxic ventilatory drive in normal man. J Clin Invest 1970; 49: 1061-1072.

12. Moosavi SH, Golestanian E, Binks AP, Lansing RW, Brown R, Banzett RB. Hypoxic and hypercapnic drives to breathe generate equivalent levels of air hunger in humans. J Appl Physiol 2003; 94: 141-154.

13. Mohan R, Duffin J. The effect of hypoxia on the ventilatory response to carbon dioxide in man. Respir Physiol 1997; 108: 101-115.

14. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020: Apr 22. doi:10.1001/jama.2020.6775.

15. Kronenberg RS, Drage CW. Attenuation of the ventilatory and heart rate responses to hypoxia and hypercapnia with aging in normal men. J Clin Invest 1973; 52: 1812-1819.
16. Peterson DD, Pack AI, Silage DA, Fishman AP. Effects of aging on ventilatory and occlusion pressure responses to hypoxia and hypercapnia. *Am Rev Respir Dis* 1981; 124: 387-391.

17. Nishimura M, Miyamoto K, Suzuki A, Yamamoto H, Tsuji M, Kishi F, Kawakami Y. Ventilatory and heart rate responses to hypoxia and hypercapnia in patients with diabetes mellitus. *Thorax* 1989; 44: 251-257.

18. Weisbrod C, Eastwood P, O'Driscoll G, Green D. Abnormal ventilatory responses to hypoxia in Type 2 diabetes. *Diabet Med* 2005; 22: 563-568.

19. O'Donnell CR, Friedman LS, Russomanno JH, Rose RM. Diminished perception of inspiratory-resistive loads in insulin-dependent diabetics. *N Engl J Med* 1988; 319: 1369-1373.

20. Tobin MJ, Mador MJ, Guenther SM, Lodato RF, Sackner MA. Variability of resting respiratory drive and timing in healthy subjects. *J Appl Physiol* 1988; 65: 309-317.

21. Swenson ER, Duncan TB, Goldberg SV, Ramirez G, Ahmad S, Schoene RB. Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones. *J Appl Physiol* 1995; 78: 377-383.

22. Matsuzawa Y, Fujimoto K, Kobayashi T, Namushi NR, Harada K, Kohno H, Fukushima M, Kusama S. Blunted hypoxic ventilatory drive in subjects susceptible to high-altitude pulmonary edema. *J Appl Physiol* 1989; 66: 1152-1157.
23. McGurk S, Blanksby B, Anderson M. The relationship of hypercapnic ventilatory responses to age, gender and athleticism. *Sports Med* 1995; 19: 173-183.

24. Jubran A, Tobin MJ. Effect of isocapnic hypoxia on variational activity of breathing. *Am J Respir Crit Care Med* 2000; 162: 1202-1209.

25. Bickler PE, Feiner JR, Lipnick MS, Batchelder P, MacLeod DB, Severinghaus JW. Effects of acute, profound hypoxia on healthy humans: implications for safety of tests evaluating pulse oximetry or tissue oximetry performance. *Anesth Analg* 2017; 124: 146-153.

26. Jubran A. Pulse oximetry. In: Tobin MJ, editor. Principles and Practice of Intensive Care Monitoring. New York: McGraw-Hill, Inc.; 1998. p. 261-287.

27. Ottestad W, Hansen TA, Pradhan G, Stepanek J, Høiseth LØ, Kåsin JI. Acute hypoxia in a simulated high-altitude airdrop scenario due to oxygen system failure. *J Appl Physiol* 2017; 123: 1443-1450.

28. Ottestad W, Kåsin JI, Høiseth LØ. Arterial oxygen saturation, pulse oximetry, and cerebral and tissue oximetry in hypobaric hypoxia. *Aerospace Med Hum Perform* 2018; 89: 1045-1049.

29. Louw A, Cracco C, Cerf C, Harf A, Duvaldestin P, Lemaire F, Brochard L. Accuracy of pulse oximetry in the intensive care unit. *Intensive Care Med* 2001; 27: 1606-1613.

30. Jubran A, Tobin MJ. Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients. *Chest* 1990; 97: 1420-1425.
31. Kelman GR. Digital computer subroutine for the conversion of oxygen tension into saturation. *J Appl Physiol* 1966; 21: 1375-1376.

32. Fung ML. Expressions of angiotensin and cytokine receptors in the paracrine signaling of the carotid body in hypoxia and sleep apnea. *Respir Physiol Neurobiol* 2015; 209: 6-12.

33. Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance. *Otolaryngol Head Neck Surg* 2020; 5: May 5. doi: 10.1177/0194599820926464.

34. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J Virol* 2008; 82: 7264-7275.

35. Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. *Ann Intern Med* 2020: May 6;M20-2003. doi: 2010.7326/M2020-2003. Online ahead of print. PMID: 32374815.

36. Sanchez O, Caumont-Prim A, Riant E, Plantier L, Dres M, Louis B, Collignon MA, Diebold B, Meyer G, Peiffer C. Pathophysiology of dyspnoea in acute pulmonary embolism: A cross-sectional evaluation. *Respirology* 2017; 22: 771-777.

37. Stedman's Medical Dictionary. 25 ed. Baltimore: Williams & Wilkins; 1990. p. p.756.

38. Sorbini C, Grassi V, Solinas E, G M. Arterial oxygen tension in relation to age in healthy subjects. *Respiration* 1968; 25: 3-13.
39. Malmberg P, Hedenström H, Fridriksson H. Reference values for gas exchange during exercise in healthy nonsmoking and smoking men. *Bull Eur Physiopathol Respir* 1987; 23: 131-138.

40. West JB. Pulmonary pathophysiology. Baltimore: Williams and Wilkins; 1977 p.: p.158.

41. Murray JF. The normal lung. 2nd ed. Philadelphia: WB Saunders; 1986. p. p.253.

42. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. *Respir Care* 2000; 45: 39-53.

43. Bazuaye EA, Stone TN, Corris PA, Gibson GJ. Variability of inspired oxygen concentration with nasal cannulas. *Thorax* 1992; 47: 609-611.

44. Severinghaus JW. Simple, accurate equations for human blood O2 dissociation computations. *J Appl Physiol* 1979; 46: 599-602. (revisions 1999, 2002, 2007).

45. Tobin MJ. Why physiology is critical to the practice of medicine: a 40-year personal perspective. *Clin Chest Med* 2019; 40: 243-257.
Figure 1. The ventilatory response to progressive isocapnic hypoxia in a healthy subject. Little change in minute ventilation ($V_E$) is noted until alveolar oxygen tension ($P_{A\text{O}_2}$) falls to 60 mmHg, and thereafter the response is very steep. Each data point represents the mean value for $P_{A\text{O}_2}$ and $V_E$ for three successive breaths. From Weil et al (11), with permission. Figure 1.
Figure 2 Scatterplot of the relationship between estimated oxygen saturation from pulse oximetry (SpO₂) and arterial oxygen saturation from blood gas analysis (SaO₂) in healthy subjects exposed to profound hypoxemia in a hypobaric chamber (arterial oxygen tension PaO₂, 21.6–27.8 mmHg). Each subject is represented by a different symbol. The dashed line is the line of identity and the solid line is the regression line. From Ottestad et al (28), with permission.
Figure 3 Relationship between arterial oxygen tension (PaO$_2$) and percentage saturation of hemoglobin with oxygen (SaO$_2$) at temperature 37°C (continuous line) and 40°C (dotted line), with constant pH 7.40 and PCO$_2$ 40 mmHg (generated with digital subroutine of Kelman (31)). At PaO$_2$ 60 mmHg, SaO$_2$ is 91.1% at 37°C and decreases to 85.8% at 40°C. At PaO$_2$ 40 mmHg, SaO$_2$ is 74.1% at 37°C and decreases to 64.2% at 40°C.